Internationally recognized leaders in the field, our depth of expertise and services accelerate the discovery and development of drug in prostate cancer.
Alfa Cytology offers the value of flexibility to provide a range of solutions as a full-service prostate cancer research organization.
At Alfa Cytology, we provide tailored development services in prostate cancer.
Internationally recognized leaders in the field, our depth of expertise and services accelerate the discovery and development of drug in prostate cancer.
Our company is deeply engaged in the research field of therapies development in prostate cancer, and keep track of cutting-edge technology in this field.
We provide 24-hour one-stop develop ment services. Any time you need help, you may contact us and we will offer the best services for you.
We offer expertise in therapies development targeted to AR signaling axis in prostate cancer, such as AR signaling inhibitor development and GnRH antagonists/agonists development.
We specialize in inhibitors development for prostate cancer that target PI3K/AKT/MTOR signaling pathway, such as PI3K, AKT, mTOR and PIM, to inhibit prostate cancer progression.
Our company is deeply engaged in the research field of epigenetic Inhibitor for prostate cancer,especially in the five key targets of EZH2, LSD1, BET, HDAC and DNMT.
In the field of prostate cancer growth in bone microenvironments, our company has extensive experience and cutting-edge technologies, with a special focus on key targets such as RANKL/RANK pathway, ETAR and Calcium Channel.
Our service focus on other therapeutic target modulator development in prostate cancer, with a particular focus on key targets such as PARP, PSMA, CDK and immune checkpoint.
Prostate cancer is divided into the following types based on differences in cell type.